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In 1994, the U.S. Cystic Fibrosis Foundation sponsored a
consensus conference (33) on microbiology and infectious dis-
ease in patients with cystic fibrosis (CF), a homozygous reces-
sive disease in individuals of Caucasian descent. The organi-
zation of that conference followed the recognition that the
discovery of the CF gene in 1989 was not going to yield a quick
cure for CF and that chronic pulmonary infection was the
primary culprit in the early mortality associated with this dis-
ease. The resulting document made recommendations for the
detection, isolation, identification, and susceptibility testing of
organisms recognized as significant or potentially significant in
the lung diseases of this patient population. The microbial
species that are clearly associated with lung disease in CF
patients (CF lung disease) are relatively few, including Staph-
ylococcus aureus, Pseudomonas aeruginosa, and Burkholderia
cepacia complex (Table 1). Organisms having a secondary role
in CF lung disease include respiratory viruses, such as respira-
tory syncytial virus and influenza virus; Haemophilus influen-
zae; and Aspergillus fumigatus. Mycobacterium spp. but not My-
cobacterium tuberculosis, Stenotrophomonas maltophilia, and
Alcaligenes xylosoxidans are being seen with increasing fre-
quencies in CF patients, in part because of the increasing life
spans of CF patients and the relentless use of antimicrobial
agents in this patient population. However, the role of the
latter organisms in CF lung disease has not been clearly de-
termined. In addition, organisms that phenotypically resemble
B. cepacia complex organisms (i.e., Burkholderia gladioli, Ral-
stonia spp., and Pandoraea spp.) are also being seen with in-
creasing frequencies due to the use of selective media that
improve the rates of recovery of B. cepacia complex isolates.
These media also improve the rates of recovery of these other
species. Although there are no data that suggest that these
non-B. cepacia complex organisms play a role in CF lung dis-
ease, these organisms are difficult to differentiate phenotypi-
cally from B. cepacia complex. As we will review, misidentifi-
cation of these seemingly harmless saprophytes as B. cepacia
complex organisms may have profound consequences for the
patient. This minireview discusses the state of the art in the
laboratory diagnosis of the infectious agents associated with
CF lung disease.
STAPHYLOCOCCUS AUREUS
S. aureus was the first pulmonary pathogen recognized in
patients with CF. During the preantibiotic era, the organism
was frequently found in the lungs of young children at autopsy.
With the development of antistaphylococcal penicillins, the
rates of morbidity and particularly the rates of mortality due to
S. aureus declined (14). S. aureus continues to be a frequently
encountered pathogen, recovered from approximately 50% of
CF patients (11). Laboratorians should be familiar with two
issues concerning S. aureus in this patient population: the de-
creased reliability of S. aureus recovery and the frequency of
oxacillin-resistant isolates.
It has been recognized for close to 20 years that auxotrophic
forms of S. aureus are recovered with increased frequencies
from the respiratory tracts of CF patients (15). Individuals
harboring these auxotrophic isolates generally have received
long-term antistaphylococcal therapy, typically trimethoprim-
sulfamethoxazole. In the earlier CF literature, these organisms
were described as thymidine-dependent isolates. More recent
literature describes these auxotrophic organisms as small-col-
ony variants (22). Kahl and colleagues (22) reported that
small-colony variants could be recovered from up to 50% of
CF patients harboring S. aureus. These organisms yield small,
nonhemolytic, nonpigmented, slowly growing colonies on en-
riched media such as sheep blood or chocolate agars, thus
making these isolates difficult to recognize as S. aureus. The
selective medium mannitol salts agar supports the growth of S.
aureus auxotrophs and prevents the overgrowth of S. aureus
isolates by gram-negative rods such as P. aeruginosa and B.
cepacia complex. Thus, mannitol salts agar should be used for
the recovery of S. aureus in cultures of all respiratory tract
specimens from CF patients.
Oxacillin-resistant strains are being seen with increasing fre-
quency in CF patients. Approximately 6% of S. aureus isolates
recovered from CF patients nationally are oxacillin resistant,
with some centers (including our own) reporting that 20% of
isolates are resistant (11). Molecular epidemiology studies
show that CF patients harboring oxacillin-resistant S. aureus
isolates frequently acquire the isolate while they are hospital-
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ized. Some patients become chronically infected with these
organisms, while others may be only transiently infected (16).
PSEUDOMONAS AERUGINOSA
P. aeruginosa is the most important pathogen of CF lung
disease, infecting approximately 60% of the entire CF popu-
lation and close to 80% of adolescents and adults (26). Studies
have shown that P. aeruginosa infections in CF patients can be
seen as early as infancy (4). The initial strains of P. aeruginosa
that infect CF patients are described as “rough” or “plankton-
ic” strains. These strains tend to be sensitive to a variety of
antimicrobials, are motile and prototrophic, and have smooth
lipopolysaccharide. It is at this stage that some investigators
believe that aggressive antimicrobial therapy can eradicate this
organism (13). However, most patients develop chronic infec-
tion with an unusual phenotype of P. aeruginosa referred to as
“mucoid” (Fig. 1). Mucoid isolates are nonmotile, are fre-
quently auxotrophic, have rough lipopolysaccharide, and are
frequently resistant to a wide variety of antimicrobial agents
(37). Mucoid strains of P. aeruginosa grow as biofilms in the
airways of CF patients. Examination of sputa from patients
FIG. 1. Use of BCSA improves recovery of B. cepacia complex. (Left) MacConkey agar demonstrating overgrowth by a mucoid strain of P.
aeruginosa; (right) BCSA showing the growth of B. cenocepacia (genomovar III) that cannot be visualized on the corresponding MacConkey agar.
TABLE 1. Potential pathogens and related organisms that can be detected in the respiratory tracts of CF patients
Organism Frequency (%)of isolation
% of laboratories
that culturea CF population
Role in CF lung
disease
P. aeruginosa 59b 95 All Proven
S. aureus 48 100 Predominantly children and adolescents Proven
B. cepacia complex 3 98 Predominantly adolescents and adults Proven
S. maltophilia 8.40 97 Predominantly adolescents and adults Unknown
A. xylosoxidans unknown NRc Predominantly adolescents and adults Unknown
B. gladioli 1 NR Predominantly adolescents and adults Unlikely
Ralstonia spp. 1 NR Predominantly adolescents and adults Unlikely
Pandoraea spp. 1 NR Predominantly adolescents and adults Unlikely
Mycobacterium spp. but not
M. tuberculosis
13d NR Predominantly adolescents and adults Provend
H. influenzae 15b 100 Children Likely
A. fumigatus 9e 100 All Provenf
Respiratory syncyntial virus unknown NR Children Proven
Influenza virus unknown NR All Proven
a Percentage of laboratories that culture specimens from CF patients for the specific organism either routinely or by request. Data are from reference 34.
b The data are from reference 11.
c NR, not reported.
d Requires high organism loads, as evidenced by three positive cultures or two positive cultures with a positive smear (30).
e The datum is from reference 10.
f Allergic bronchopulmonary aspergillosis.
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chronically infected with mucoid strains of P. aeruginosa reveal
gram-negative rods in small clusters surrounded by amorphous
material that stains Gram negative. This material is a polysac-
charide polymer referred to as alginate, which forms the bio-
film matrix and renders the embedded Pseudomonas organisms
refractory to clearance by the immune system (14). The pres-
ence of mucoid strains of P. aeruginosa signals the beginning of
the chronic phase of infection (26). The chronic phase of
infection due to P. aeruginosa is characterized by pulmonary
exacerbations (fever, elevated white blood cell count, in-
creased sputum production, and decreased pulmonary func-
tion) that require antimicrobial therapy. CF exacerbations are
typically interspersed with intervening periods of relative qui-
escence, with each phase lasting various lengths of time. How-
ever, lung function continuously declines, the infecting strains
become increasingly resistant, and inevitably, the patient suc-
cumbs to cardiopulmonary failure. There is a growing consen-
sus that the lung pathology that occurs during chronic P.
aeruginosa infection is due to a large extent to the immune
response directed against pseudomonal biofilms. High levels of
cytokines and leukocyte-derived proteases can be detected in
airway fluid from CF patients and are believed to be respon-
sible for much of the lung damage that occurs in this patient
population (26).
Isolation of P. aeruginosa from the respiratory secretions of
CF patients is easily accomplished, with both rough and mu-
coid isolates being readily recovered on agar selective for
gram-negative organisms, such as MacConkey and eosin-meth-
ylene blue agars. Presumptive identification is relatively easily
accomplished on the basis of a positive oxidase test, pigment
production, growth at 42°C, and, in some cases, mucoid colony
morphology. However, as chronic infection progresses, some
strains lose the ability to produce pigments as well as other
phenotypic characteristics. The loss of these phenotypes is
most likely an evolutionary process in which the corresponding
genes are either down-regulated or lost in a nutrient-rich en-
vironment. As a result of this evolutionary change, it may
become difficult to identify these strains of P. aeruginosa with
commercial identification systems. As many as 15% of P.
aeruginosa strains recovered from CF patients could not be
accurately identified with the MicroScan Autoscan system
(Dade International Inc., West Sacramento, Calif.), even after
extended (48-h) incubation (31). Interestingly, in that study
many isolates were misidentified as Alcaligenes spp., an organ-
ism that can be recovered from the sputum of CF patients but
whose clinical significance has not been determined (31).
These data suggest that the use of commercial systems should
be applied cautiously to the identification of suspected P.
aeruginosa isolates.
Susceptibility testing of P. aeruginosa isolates recovered
from CF patients is an area of some controversy. Multiple
morphotypes may be recovered from patient sputum. Studies
that compared the performance of susceptibility testing of a
mixture of different morphotypes versus the performance of
testing of each morphotype individually suggest that testing of
mixed morphotypes may underestimate resistance (29). It is
unclear how widespread the practice of testing individual mor-
photypes is in laboratories that culture specimens from CF
patients. Recent investigations suggest that a variety of com-
mercial susceptibility testing systems, E-test, and disk diffusion
work well compared to a reference MIC method for determi-
nation of the susceptibilities of P. aeruginosa isolates recovered
from CF patients (5, 6).
The impacts of two areas of investigation on P. aeruginosa
susceptibility testing and interpretation have not been re-
solved. The first is a study that suggests that P. aeruginosa
grows anaerobically within the airways of CF patients (41). If
that is true, aminoglycosides should not be active against those
organisms, regardless of their in vitro activities. This directly
conflicts with numerous data in the CF literature that both
aerosolized and intravenously administered aminoglycosides
have a positive impact on the lung functions and life expect-
ancies of CF patients (7). However, anaerobically growing P.
aeruginosa isolates may contribute to this organism’s ability to
persist in the lungs of CF patients in the face of high concen-
trations of aminoglycosides. The second area of investigation
has been determination of the microbial form of P. aeruginosa
that should be used for susceptibility testing. Recently, equip-
ment called the “Calgary device” has been developed that
allows susceptibility testing to be performed with mucoid P.
aeruginosa isolates growing as biofilms. The susceptibilities of
mucoid P. aeruginosa isolates growing as biofilm have been
compared to those of strains growing planktonically, which are
used in clinical laboratory susceptibility testing. Biofilm strains
were significantly more resistant to antipseudomonal drugs.
The number of isolates tested was quite small, and no clinical
correlations were presented. However, these data suggest that
susceptibility results obtained by testing planktonically growing
isolates may underestimate the drug resistance of mucoid P.
aeruginosa (1).
BURKHOLDERIA CEPACIA COMPLEX AND
RELATED ORGANISMS
B. cepacia was first described as a significant pathogen
among CF patients in 1984 (21). Subsequent studies have
shown that B. cepacia includes at least nine genomovars, or
genomic species, collectively referred to as B. cepacia complex.
Although only 3% of American CF patients and 15% of
the Canadian CF population are colonized with B. cepacia
complex, the repercussions of infection are extensive. In CF
patients, infection with B. cepacia complex is associated with
increased rates of morbidity and mortality. Roughly 20% of CF
patients colonized with B. cepacia complex develop the “cepa-
cia syndrome” (36). These patients experience a rapid decline
in pulmonary function, frequent bacteremia, and, ultimately,
death due to lung failure. Of additional concern is the person-
to-person transmission of B. cepacia complex among CF pa-
tients. Person-to-person spread has been documented within
CF centers, regionally, and intercontinentally (9). Infection
with B. cepacia complex can have devastating consequences for
CF patients, as colonized patients are excluded from social
events and scientific conferences for CF patients and are re-
jected as potential lung transplant recipients at many CF cen-
ters due to potentially poor outcomes (8). Therefore, it is
crucial that laboratory identification of B. cepacia complex
from specimens from CF patients be performed with utmost
accuracy.
Unfortunately, the diversity of B. cepacia complex organisms
has made precise isolation and identification difficult. Geno-
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movars are organisms that are genetically distinct but that are
difficult to distinguish phenotypically and therefore may be
differentiated only by molecular testing. However, eight of the
nine genomovars have been given a species designation on the
basis of phenotypic or genomic characterization. A summary of
the nine genomovars, including their species designations and
potential roles in CF disease, is provided in Table 2 (38).
Although genomovars I to VIII have each been isolated from
the lungs of CF patients, it is interesting that only Burkholderia
multivorans (genomovar II) and Burkholderia cenocepacia
(genomovar III) have a distinct correlation with CF lung dis-
ease. Together, B. multivorans and B. cenocepacia constitute
over 85% of B. cepacia complex isolates recovered from CF
patients, with B. cenocepacia representing 50% (18). In ad-
dition, a B. cenocepacia clone expressing a rare adhesin called
cable pilin is associated with increased transmission and was
the clone identified in intercontinental spread (35). A poor
prognosis posttransplantation is also associated with B. ceno-
cepacia infection (2). These data suggest that only patients
harboring B. cenocepacia (genomovar III) should be excluded
from lung transplantation.
Isolation of B. cepacia complex from respiratory secretions
from CF patients has improved with the use of selective media.
Three media, Pseudomonas cepacia (PC) agar, oxidative-fer-
mentative base, polymyxin B, bacitracin, and lactose (OFPBL)
agar, and B. cepacia selective agar (BCSA), are used to recover
B. cepacia complex isolates from respiratory specimens from
CF patients. These media inhibit the growth of other potential
pathogens of CF patients, such as P. aeruginosa, which often
grows more rapidly and in larger quantities than members of B.
cepacia complex and therefore may mask its presence (Fig. 1).
A multicenter analysis of the three selective media demon-
strated increased sensitivity and specificity of BCSA over both
PC agar and OFPBL agar in the recovery of B. cepacia com-
plex. Therefore, BCSA is the preferred medium for isolation of
B. cepacia complex (19).
Once isolated, B. cepacia complex poses the problem of
accurate identification. In addition to the challenge of distin-
guishing between B. cepacia genomovars, differentiation must
be made between B. cepacia complex and other phenotypically
similar organisms, such as B. gladioli, Ralstonia spp., and Pan-
doraea spp. Although these B. cepacia-like organisms have
been isolated in cultures of respiratory specimens from CF
patients (28), at present, no data that support their role as
pulmonary pathogens in this patient population.
Typical identification schemes for B. cepacia complex in-
clude the use of selective media along with conventional bio-
chemical analysis and/or commercial bacterial identification
systems. Growth on BCSA should not be used to definitively
identify B. cepacia complex, as B. gladioli and Ralstonia species
can also grow on BCSA. However, the use of BCSA provides
a first screen for the presence of B. cepacia-like organisms in
cultures of respiratory specimens from CF patients, and fur-
ther characterization of these isolates should follow. B. gladioli,
Ralstonia spp., and Pandoraea spp. can be differentiated from
B. cepacia by biochemical analysis, but phenotypic variation
within each species may cause identification difficulties. Con-
ventional biochemical tests can also differentiate several B.
cepacia genomovars, but similarly, phenotypic variation within
each genomovar makes biochemical analysis unreliable as a
sole identification scheme. Although genetically distinct, geno-
movars I and III cannot be separated phenotypically, and
genomovars II and VI are phenotypically indistinguishable.
Commercial identification systems are inadequate for differ-
entiation among B. cepacia complex genomovars and often
cannot distinguish B. cepacia complex members from B. cepa-
cia-like organisms. Commercial test system identification of B.
cepacia should be corroborated with growth on selective media
and a supplemental biochemical battery.
Definitive identification of B. cepacia genomovars relies on
molecular analysis. Differentiation of B. cepacia complex from
other similar organisms can be accomplished by whole-cell
protein analysis, whole-cell fatty acid analysis, and/or 16S
rRNA gene sequencing. To identify B. cepacia to the genomo-
var level molecularly, techniques such as amplified fragment
length polymorphism fingerprinting or recA restriction frag-
ment length polymorphism analysis must be applied. Of inter-
est, recent research has demonstrated progress toward direct
detection of B. cepacia genomovars in the sputum of CF pa-
tients by PCR (12, 27). Although these techniques are often
not suitable for use in the clinical laboratory, molecular iden-
tification of presumed B. cepacia isolates is available through
the Cystic Fibrosis Foundation B. cepacia Research Laboratory
and Repository (J. J. LiPuma, University of Michigan Medical
School).
B. cepacia complex is commonly panresistant to antimicro-
bial agents, including cephalosporins and aminoglycosides,
therefore making treatment challenging. High-level resistance
to multiple antibiotics by B. cepacia complex is achieved
through a combination of mechanisms, including selective cell
wall permeability, cellular target alteration, enzymatic inacti-
vation of antibiotics, and drug efflux pumps. B. cepacia strains
that have not been challenged with antibiotics are typically
susceptible only to piperacillin, piperacillin-tazobactam, ce-
foperazone, ceftazidime, chloramphenicol, and trimethoprim-
sulfamethoxazole, with variable susceptibilities to imipenem
and meropenem. Remarkably, strains isolated after multiple
antimicrobial treatments are often resistant to all known anti-
biotics. Thus, eradication of B. cepacia complex infections is
difficult, if not impossible, making prevention of infection via
aggressive infection control practices critical. For example, CF
clinics often schedule appointments for patients colonized with
B. cepacia complex either at the end of the day or on different
clinic days or at different locales, therefore limiting contact
with other outpatients. It is also recommended that CF pa-
tients not share inpatient rooms and that B. cepacia-infected
TABLE 2. B. cepacia complex
Genomovar Speciesdesignation
Role in CF lung
disease
I B. cepacia Unlikely
II B. multivorans Proven
III B. cenocepacia Proven
IV B. stabilis Unlikely
V B. vietnamiensis Unlikely
VI Unnamed Unlikely
VII B. ambifaria Unlikely
VIII B. anthina Unlikely
IX B. pyrrocinia Unknown
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CF inpatients not have direct contact with non-B. cepacia-
infected CF inpatients, especially in settings such as playrooms
and hospital lounges. Patient segregation and infection control
have been proven to prevent the transmission of B. cepacia
complex among CF patients. However, of critical importance is
the correct laboratory identification of B. cepacia complex in-
fection in the CF population. A false-positive identification has
unnecessary ramifications both psychologically and socially on
the CF patient and his or her family, and a false-negative
identification could profoundly affect the entire CF commu-
nity.
STENOTROPHOMONAS AND ALCALIGENES
S. maltophilia and Alcaligenes spp. are both being seen with
increasing frequencies, primarily in the adult CF population
(17, 32). However, the role of either of these agents in CF lung
disease has not been determined by case-control studies, as has
been done with B. cepacia complex. Identification of S. malto-
philia and Alcaligenes spp. isolated from CF respiratory speci-
mens can be problematic. Several studies have demonstrated
that both S. maltophilia and Alcaligenes spp. can be misidenti-
fied by clinical laboratories as B. cepacia complex, and vice
versa (28). Identification is partially complicated by the growth
of some S. maltophilia and Alcaligenes spp. strains on B. cepacia
selective media such as OFPBL and PC agars. Similar to B.
cepacia complex, both S. maltophilia and Alcaligenes spp. are
often resistant to a wide variety of antimicrobial agents. Sus-
ceptibility testing of S. maltophilia should be performed by an
MIC method, since very major errors may be seen when disk
diffusion is performed by using P. aeruginosa breakpoints (i.e.,
reporting as susceptible an isolate that might be resistant) (3,
25). Clinicians caring for CF patients are interested in knowing
if these organisms are present, and in some clinical situations,
physicians target antimicrobial therapy to eradicate these bac-
teria.
HAEMOPHILUS INFLUENZAE
H. influenzae is the third most commonly recovered bacte-
rium from the respiratory tracts of CF patients (15% of
patients) (11). This organism is typically recovered from chil-
dren with CF and is infrequently seen in adults with CF. The
inability to detect H. influenzae in adults with CF could be
explained by the organism being obscured by mucoid P. aerugi-
nosa. Three strategies for growing H. influenzae from respira-
tory specimens from CF patients have been proposed: the use
of chocolate agar supplemented with bacitracin, incubation of
plates anaerobically to suppress the growth of P. aeruginosa, or
performance of quantitative cultures (33, 40). Bacitracin-sup-
plemented chocolate agar plates allow the growth of P. aerugi-
nosa, and their use is of limited value for patients chronically
infected with P. aeruginosa. Anecdotal experience at the Clin-
ical Microbiology-Immunology Laboratories of University of
North Carolina Hospitals is that anaerobic incubation of choc-
olate agar plates with specimens from CF patients infected
with P. aeruginosa did not enhance the recovery of H. influen-
zae. Our experience also indicates that H. influenzae can be
recovered from quantitatively cultured, bronchoscopically ob-
tained specimens from children with CF, but this organism is
rarely recovered from adults with CF. Despite its relatively
frequent recovery from children with CF, there are few data to
support a primary role for this organism in CF lung disease
(26).
ASPERGILLUS SPP. AND OTHER FUNGI
Filamentous fungi are frequently recovered from respiratory
specimens from CF patients, especially with the increased use
of B. cepacia selective agars, which support fungal growth.
Only Aspergillus spp. have been recognized as being associated
with pulmonary symptoms in CF patients. Organism of this
genus are associated with an entity called allergic bronchopul-
monary aspergillosis. The diagnosis of this entity is based on
clinical criteria rather than the recovery of the organism. Pa-
tients may harbor Aspergillus spp. without having this syndrome
(24). Therefore, documentation of the presence of filamentous
fungi in this patient population is of limited value.
MYCOBACTERIUM SPP.
M. tuberculosis is rarely recovered from CF patients, and this
patient population does not appear to be at increased risk for
infection by this organism. However, a case series in the early
1990s, along with several case reports, suggests that Mycobac-
terium avium complex and rapidly growing mycobacterial spe-
cies are recovered from as many as 20% of CF patients (23). In
order to ensure the recovery of nontuberculous mycobacteria
from CF patients, stringent decontamination conditions are
needed due to P. aeruginosa contamination of mycobacterial
cultures. Sequential treatment of respiratory specimens with
standard N-acetyl cysteine–NaOH followed by oxalic acid
treatment has been shown to significantly increase the rate of
recovery of nontuberculous mycobacteria by reducing P.
aeruginosa overgrowth (39). By using this culture technique, a
multicenter prevalence study showed that 13% of CF patients
were culture positive for nontuberculous mycobacteria. Pa-
tients with higher organism burdens, indicated by positive
smears or multiple positive cultures, were more likely to have
changes on high-resolution chest computed tomography but
did not have significant declines in lung function. Nevertheless,
these patients may benefit from antimycobacterial therapy
(30).
VIRAL INFECTIONS
Both influenza and respiratory syncytial viruses have been
reported to be associated with pulmonary exacerbations in CF
patients (20). Studies of viral disease in CF patients have de-
pended on either serology or viral culture. There is a heavy
reliance on serologic data since viral cultures tend to be posi-
tive less frequently for CF patients than for non-CF patient
controls (20). If newer antiviral agents active against influenza
virus are to be used in a cost-effective manner in this patient
population, antigen detection or molecular amplification tests
will need to be used. The reliability of either of these ap-
proaches has not yet been systematically studied for this pa-
tient population.
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PRACTICAL APPROACHES TO MICROBIOLOGY FOR
CF PATIENTS
With the requirement that at least two selective media (man-
nitol salts agar for S. aureus and BCSA for B. cepacia complex)
be used, in addition to the standard battery of isolation media,
and the need to identify and perform susceptibility testing with
multiple isolates, culture of respiratory tract specimens from
CF patients is one of the most labor-intensive and expensive
culture procedures performed in the clinical microbiology lab-
oratory. Over the past 10 years, in collaboration with our phy-
sicians caring for CF patients, we have developed a strategy to
try to limit our costs while at the same time delivering high-
quality microbiology services for this patient population.
The first part of our strategy is to eliminate routine Gram
stains from cultures of all sputum specimens from CF patients,
other than those who have recently received lung transplants.
We found that few specimens were rejected (a major reason
for doing a sputum Gram stain), and the organisms seen by
Gram staining were highly predictable.
The second part of our strategy is to limit the workup of
cultures respiratory specimens from both CF outpatients and
CF inpatients. An extensive culture workup (i.e., complete
identification and susceptibility testing of significant isolates
[Table 1]) is done every 3 months for outpatients. Cultures of
outpatient specimens (sputum and deep pharyngeal speci-
mens) submitted less than 3 months after an extensive workup
are sight read and reported, with identification and sensitivity
testing done only by physician request. The same strategy is
also used for CF inpatients; the initial sputum and deep pha-
ryngeal specimens receive an extensive workup, but subse-
quent sputum and deep pharyngeal specimens are sight read.
Bronchoscopy specimens are obtained at some expense and
danger to the patient and are considered “gold standard” spec-
imens. Therefore, cultures of sputum and deep pharyngeal
specimens are sight read, as described above, for patients for
whom culture of a bronchoscopy specimen had been per-
formed within the previous 3 months for outpatients and dur-
ing a hospital stay for inpatients. In addition, identification of
molds recovered from CF patients is limited to once per cal-
endar year. Many of these patients have long-term colonization
with Aspergillus spp., and repeated identification has no clinical
relevance. Physicians always have the option, after consultation
with the laboratorian, to request further workup for any spec-
imen submitted to the laboratory; but in our experience, this is
a relatively uncommon occurrence. It should be noted that
strategies for performing cultures with specimens from CF
patients who have received lung transplants are very different,
and discussion of those strategies is beyond the scope of this
review.
Since susceptibility testing also results in significant expense,
this is the focus of our third strategy. Complete S. aureus
susceptibility testing is performed once per calendar year. Oth-
erwise, isolates are screened for resistance by using an oxacillin
screening plate. The first time that a patient’s S. aureus isolate
is oxacillin resistant, as detected by screening, complete sus-
ceptibility testing is performed. As described above, suscepti-
bility testing of P. aeruginosa isolates from CF patients is chal-
lenging. Similar to our identification scheme, we perform
susceptibility testing by disk diffusion for each morphotype of
P. aeruginosa once every 3 months for outpatients or at admis-
sion for inpatients. The same strategy is used for A. xylosoxi-
dans, B. cepacia complex, and related organisms, although the
caveat “nonstandardized susceptibility” is added to alert the
physician that very major errors are possible. As mentioned
above, S. maltophilia susceptibility testing must be performed
by MIC methodologies. Using P. aeruginosa susceptibility
breakpoints, we use E-tests and test only three drugs, ceftazi-
dime, trimethoprim-sulfamethoxazole, and ticarcillin-clavu-
lanic acid. Because both B. cepacia complex and P. aeruginosa
isolates may be resistant to multiple antibiotics, physicians
often request synergy testing for these isolates to determine
the very best antimicrobial combination with which to treat
these patients. To that end, the U.S. Cystic Fibrosis Founda-
tion has established a reference laboratory where this testing is
performed without charge. For more information on this ser-
vice, visit the U.S. Cystic Fibrosis Foundation website at www
.cff.org.
In summary, the microbiology of pulmonary disease in CF
patients has multiple layers of complexity. In addition to the
number of different bacterial species isolated from respiratory
specimens from this patient population, the intra- and inter-
species interactions are also numerous. The formation of bio-
films and anaerobic growth conditions in the lungs of CF pa-
tients threaten to discount the in vitro susceptibility data
generated for bacterial isolates from CF patients. As we have
addressed, there are also problems associated with the isola-
tion and identification of these organisms in the face of evo-
lutionary change. However, it should be noted that diligent
research toward the understanding of the microbiology and
physiology of CF patients not only has led to an extended life
span for many CF patients but also has contributed to improv-
ing the quality of life for this population. The clinical labora-
tory can also contribute to the well-being of the CF population
by striving to provide high-quality, cost-effective management
of these ever-challenging cultures.
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